Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
Interferon alfa may interfere with the growth of cancer cells. Combining interferon alfa and
thalidomide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa and
thalidomide in treating patients who have undergone surgery for soft tissue sarcoma or bone
sarcoma.